Related Experiment Video
Updated: Jan 22, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Cholesterol Lowering and Stroke: No Longer Room for Pleiotropic Effects of Statins - Confirmation from PCSK9
Tanya Salvatore1, Riccardo Morganti2, Roberto Marchioli3
1Institute of Cardiology, "G. d'Annunzio" University, Chieti, Italy.
Insights
Lowering cholesterol levels significantly reduces stroke risk, regardless of the medication used. This meta-regression confirms that the extent of cholesterol reduction directly correlates with stroke risk reduction, refuting "pleiotropic" drug effects.
Area of Science:
- Cardiovascular Medicine
- Clinical Trials
- Epidemiology
Background:
- The link between cholesterol levels and stroke risk is less understood than for coronary heart disease.
- Previous studies were limited by low statistical power and less effective cholesterol-lowering interventions.
- Statin medications have shown stroke reduction, leading to theories of non-cholesterol-related "pleiotropic" effects.
Purpose of the Study:
- To analyze the relationship between changes in total cholesterol and stroke risk across various lipid-lowering interventions.
- To confirm or refute the hypothesis that cholesterol reduction itself, rather than other drug effects, impacts stroke risk.
Main Methods:
- An updated meta-regression analysis was performed on randomized trials of cholesterol-lowering treatments.
- The analysis correlated changes in total cholesterol with corresponding changes in stroke risk compared to control groups.
- Included data from recent trials like FOURIER, SPIRE-1/2, and ODYSSEY OUTCOMES.
Main Results:
- Observed relative risks for stroke in recent trials (e.g., FOURIER, SPIRE-1/2, ODYSSEY OUTCOMES) closely matched predictions from the meta-regression.
- The data demonstrated a consistent relationship between the degree of total and low-density lipoprotein cholesterol reduction and stroke risk reduction.
- No evidence supported the need for
Conclusions:
- Cholesterol reduction is the primary driver for stroke risk reduction across all lipid-lowering interventions.
- The observed stroke risk reduction is directly proportional to the extent of cholesterol lowering achieved.
- This confirms that specific lipid-lowering effects, not
Background:
The relationship between cholesterol levels and stroke has been much less clear than the relationship between cholesterol levels and coronary heart disease. This is likely mostly due to the inadequate power of older studies and the low intensity of cholesterol-lowering interventions available at the time. Because a reduction in stroke has been, conversely, clearly observed in trials with statins, for long "pleiotropic" effects of such drugs, unrelated to cholesterol lowering, have been invoked. In a previous analysis of all randomized trials of cholesterol-lowering treatments reporting on stroke we had, however, reached the conclusion that any cholesterol lowering is related to a significant reduction of stroke, in a relationship that appeared to exist for both statin and nonstatin cholesterol-lowering interventions. Outcome results of the FOURIER trial with evolocumab, SPIRE-1 and -2 with bococizumab, and ODYSSEY OUTCOMES trial with alirocumab now offer the opportunity of clearly confirming or confuting this concept.
Methods:
We here report on an updated meta-regression of the relationship of total cholesterol changes that occur with various drugs or treatments and changes in the risk of stroke compared with control.
Results:
Relative risk (RR) figure found in FOURIER, SPIRE-1/2, and ODYSSEY OUTCOMES (0.79, 0.60, and 0.79) are extremely close to the RRs of 0.79, 0.79, and 0.84, respectively, predicted by our new meta-regression.
Conclusions:
These findings offer definitive proof that the pure total (and low-density lipoprotein) cholesterol lowering, with any available lipid-lowering intervention, reduces stroke risk proportional to the extent of cholesterol reduction, without the need of invoking "pleiotropic" effects of any such treatment.
More Related Videos
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Vapor Pressure Lowering
Confirmation Biases
Cholesterol: Significance and Regulation
Considering cholesterol and...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Effects of Temperature on Free Energy

